Literature DB >> 8223885

Tachykinins mediate contraction of the human lower esophageal sphincter in vitro via activation of NK2 receptors.

O Huber1, C Bertrand, N W Bunnett, C A Pellegrini, J A Nadel, P Nakazato, H T Debas, P Geppetti.   

Abstract

The contractile response to natural tachykinins and selective peptide agonists for tachykinin receptors was studied in strips of circular smooth muscle of human lower esophageal sphincter in vitro. The effects of phosphoramidon, which inhibits neutral endopeptidase (EC.3.4.24.11) and of the non-peptide compounds, SR 48968 and CP-96,345, which selectively block NK1 and NK2 receptors, respectively, were also investigated. Substance P, neurokinin A and neurokinin B produced a concentration-dependent contractile response. The rank order of potency was neurokinin A > neurokinin B > substance P. Phosphoramidon (1 microM) potentiated the response to substance P without changing the order of potency of natural tachykinins. The NK2-selective agonist, ([ beta Ala8]neurokinin A-(4-10)), produced a concentration-dependent contraction. The NK1 ([Sar9,Met(O2)11]substance P, 1 microM) and NK3 ([MePhe7]neurokinin B, 1 microM) selective agonists, however, did not exert any contractile effect. The selective NK2 antagonist, SR 48968, potently inhibited in a concentration-dependent (10 nM-1 microM) manner the response to neurokinin A, without affecting the response to carbachol. The selective NK1 antagonist, CP-96,345 (1 microM), did not affect the response to neurokinin A. These results indicate that tachykinins contract the circular muscle of human lower esophageal sphincter, and that this effect is mediated by NK2 receptor stimulation. Moreover, a phosphoramidon-sensitive mechanism plays a role in the regulation of the response to substance P.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223885     DOI: 10.1016/0014-2999(93)90982-n

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus.

Authors:  S D Smid; L A Blackshaw
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders.

Authors:  R Farré; D Sifrim
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 3.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.